Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
BerGenBio ASA ( (BRRGF) ) just unveiled an announcement.
Oncoinvent ASA has announced the completion of a significant rights issue involving 260,000,000 new shares. Key insiders and their close associates have actively participated, subscribing to substantial portions of the shares, which underscores their confidence in the company’s future prospects. This move is expected to strengthen the company’s capital base and potentially enhance its market position.
The most recent analyst rating on (BRRGF) stock is a Buy with a NOK38.00 price target. To see the full list of analyst forecasts on BerGenBio ASA stock, see the BRRGF Stock Forecast page.
More about BerGenBio ASA
Average Trading Volume: 348,417
Current Market Cap: NOK275M
Find detailed analytics on BRRGF stock on TipRanks’ Stock Analysis page.